Logo image of HRTX

HERON THERAPEUTICS INC (HRTX) Stock Fundamental Analysis

NASDAQ:HRTX - Nasdaq - US4277461020 - Common Stock - Currency: USD

1.81  0 (0%)

Fundamental Rating

2

Overall HRTX gets a fundamental rating of 2 out of 10. We evaluated HRTX against 572 industry peers in the Biotechnology industry. HRTX has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, HRTX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

HRTX had negative earnings in the past year.
In the past year HRTX has reported a negative cash flow from operations.
In the past 5 years HRTX always reported negative net income.
HRTX had a negative operating cash flow in each of the past 5 years.
HRTX Yearly Net Income VS EBIT VS OCF VS FCFHRTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50M -100M -150M -200M

1.2 Ratios

Looking at the Return On Assets, with a value of -12.67%, HRTX belongs to the top of the industry, outperforming 86.02% of the companies in the same industry.
Industry RankSector Rank
ROA -12.67%
ROE N/A
ROIC N/A
ROA(3y)-64.8%
ROA(5y)-59.72%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
HRTX Yearly ROA, ROE, ROICHRTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500 -500 -1K

1.3 Margins

The Gross Margin of HRTX (72.19%) is better than 83.72% of its industry peers.
HRTX's Gross Margin has declined in the last couple of years.
HRTX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 72.19%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.24%
GM growth 5Y-5.45%
HRTX Yearly Profit, Operating, Gross MarginsHRTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -2K -4K -6K -8K -10K

More info and screens

1

2. Health

2.1 Basic Checks

HRTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
HRTX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, HRTX has more shares outstanding
The debt/assets ratio for HRTX is higher compared to a year ago.
HRTX Yearly Shares OutstandingHRTX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M
HRTX Yearly Total Debt VS Total AssetsHRTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

2.2 Solvency

HRTX has an Altman-Z score of -10.73. This is a bad value and indicates that HRTX is not financially healthy and even has some risk of bankruptcy.
HRTX's Altman-Z score of -10.73 is on the low side compared to the rest of the industry. HRTX is outperformed by 76.81% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -10.73
ROIC/WACCN/A
WACC9.23%
HRTX Yearly LT Debt VS Equity VS FCFHRTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M -200M 400M

2.3 Liquidity

A Current Ratio of 2.28 indicates that HRTX has no problem at all paying its short term obligations.
HRTX's Current ratio of 2.28 is on the low side compared to the rest of the industry. HRTX is outperformed by 73.63% of its industry peers.
HRTX has a Quick Ratio of 1.74. This is a normal value and indicates that HRTX is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of HRTX (1.74) is worse than 78.58% of its industry peers.
Industry RankSector Rank
Current Ratio 2.28
Quick Ratio 1.74
HRTX Yearly Current Assets VS Current LiabilitesHRTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

More info and screens

6

3. Growth

3.1 Past

HRTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 81.25%, which is quite impressive.
The Revenue has grown by 12.13% in the past year. This is quite good.
Measured over the past years, HRTX shows a quite strong growth in Revenue. The Revenue has been growing by 10.39% on average per year.
EPS 1Y (TTM)81.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%82.35%
Revenue 1Y (TTM)12.13%
Revenue growth 3Y12.76%
Revenue growth 5Y10.39%
Sales Q2Q%4.38%

3.2 Future

Based on estimates for the next years, HRTX will show a very strong growth in Earnings Per Share. The EPS will grow by 20.21% on average per year.
The Revenue is expected to grow by 14.69% on average over the next years. This is quite good.
EPS Next Y85.37%
EPS Next 2Y40.16%
EPS Next 3Y29.15%
EPS Next 5Y20.21%
Revenue Next Year13.8%
Revenue Next 2Y16.26%
Revenue Next 3Y15.37%
Revenue Next 5Y14.69%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
HRTX Yearly Revenue VS EstimatesHRTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M
HRTX Yearly EPS VS EstimatesHRTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -1 -2 -3 -4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for HRTX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for HRTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HRTX Price Earnings VS Forward Price EarningsHRTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HRTX Per share dataHRTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 0.6 0.8

4.3 Compensation for Growth

A more expensive valuation may be justified as HRTX's earnings are expected to grow with 29.15% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.16%
EPS Next 3Y29.15%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for HRTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HERON THERAPEUTICS INC

NASDAQ:HRTX (2/5/2025, 11:53:05 AM)

1.81

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/bmo
Earnings (Next)02-20 2025-02-20/amc
Inst Owners82.79%
Inst Owner Change-0.02%
Ins Owners0.52%
Ins Owner Change2.64%
Market Cap275.28M
Analysts84.44
Price Target6.12 (238.12%)
Short Float %20.57%
Short Ratio9.2
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-17.65%
Min EPS beat(2)-47.06%
Max EPS beat(2)11.76%
EPS beat(4)3
Avg EPS beat(4)25.25%
Min EPS beat(4)-47.06%
Max EPS beat(4)78.21%
EPS beat(8)5
Avg EPS beat(8)13.51%
EPS beat(12)7
Avg EPS beat(12)6.71%
EPS beat(16)9
Avg EPS beat(16)5.39%
Revenue beat(2)0
Avg Revenue beat(2)-7.25%
Min Revenue beat(2)-12.91%
Max Revenue beat(2)-1.59%
Revenue beat(4)2
Avg Revenue beat(4)-0.77%
Min Revenue beat(4)-12.91%
Max Revenue beat(4)8.35%
Revenue beat(8)3
Avg Revenue beat(8)-0.4%
Revenue beat(12)5
Avg Revenue beat(12)-1.41%
Revenue beat(16)6
Avg Revenue beat(16)-4.47%
PT rev (1m)0%
PT rev (3m)-11.11%
EPS NQ rev (1m)0%
EPS NQ rev (3m)46.66%
EPS NY rev (1m)0%
EPS NY rev (3m)-7.24%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-9.89%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.52%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.18
EYN/A
EPS(NY)-0.03
Fwd EYN/A
FCF(TTM)-0.06
FCFYN/A
OCF(TTM)-0.05
OCFYN/A
SpS0.91
BVpS-0.26
TBVpS-0.26
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -12.67%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 72.19%
FCFM N/A
ROA(3y)-64.8%
ROA(5y)-59.72%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.24%
GM growth 5Y-5.45%
F-Score4
Asset Turnover0.62
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 49.92%
Cap/Sales 0.95%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.28
Quick Ratio 1.74
Altman-Z -10.73
F-Score4
WACC9.23%
ROIC/WACCN/A
Cap/Depr(3y)72.21%
Cap/Depr(5y)161.21%
Cap/Sales(3y)2.14%
Cap/Sales(5y)3.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)81.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%82.35%
EPS Next Y85.37%
EPS Next 2Y40.16%
EPS Next 3Y29.15%
EPS Next 5Y20.21%
Revenue 1Y (TTM)12.13%
Revenue growth 3Y12.76%
Revenue growth 5Y10.39%
Sales Q2Q%4.38%
Revenue Next Year13.8%
Revenue Next 2Y16.26%
Revenue Next 3Y15.37%
Revenue Next 5Y14.69%
EBIT growth 1Y78.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y93.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y94.63%
OCF growth 3YN/A
OCF growth 5YN/A